key: cord-1031090-c6v96blv authors: Coyle, Justin; Igbinomwanhia, Efehi; Sanchez-Nadales, Alejandro; Danciu, Sorin; Chu, Chae; Shah, Nishit title: A Recovered Case of COVID-19 Myocarditis and ARDS Treated with Corticosteroids, Tocilizumab, and Experimental AT-001 date: 2020-05-03 journal: JACC. Case reports DOI: 10.1016/j.jaccas.2020.04.025 sha: 89aa1309b604c2b240d8008e2e40e93bc49c4fff doc_id: 1031090 cord_uid: c6v96blv Abstract: We describe the case of a critically-ill patient with myocarditis and severe ARDS related to COVID-19 infection. This case highlights management strategies including the use of corticosteroids, an IL-6 inhibitor, and an aldose reductase inhibitor resulting in complete clinical recovery. We describe the case of a critically-ill patient with myocarditis and severe ARDS related to COVID-19 infection. This case highlights management strategies including the use of corticosteroids, an IL-6 inhibitor, and an aldose reductase inhibitor resulting in complete clinical recovery. Abbreviations and Acronyms ACS = acute coronary syndrome ARDS = acute respiratory distress syndrome ARI = aldose reductase inhibitor CAC = coronary artery calcification COVID-19 = coronavirus disease 2019 CT = computed tomography CXR = chest x-ray EF = ejection fraction LGE = late gadolinium enhancement MRI = magnetic resonance imaging NMB = neuromuscular blockade RWMA = regional wall motion abnormalities SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2 TTE = transthoracic echocardiogram Keywords: COVID-19; SARS-CoV-2; 2019-nCoV; myocarditis; ARDS; cardiogenic shock; cardiac MRI; tocilizumab; aldose reductase inhibitor; corticosteroids A 57-year-old male presented to the emergency room with shortness of breath, fevers, cough, myalgias, decreased appetite, nausea, and diarrhea for one week. The patient tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subsequently complicated by severe ARDS and acute cardiac injury. SARS-CoV-2 causing severe ARDS and acute cardiac injury from direct viral toxicity (i.e. myocarditis), acute coronary syndrome (ACS), demand ischemia, or stress cardiomyopathy. Initial evaluation revealed a positive SARS-CoV-2 test with extensive viral, bacterial, and fungal panels returning negative. Sequential chest x-rays (CXR) and computed tomography (CT) of the chest showed progressive bilateral patchy interstitial opacities ( Figure 1 ) correlating with the patient's severe hypoxia. Laboratory results were most notable for lymphopenia, elevated inflammatory markers, a rapid rise in troponin I, and elevated NT-proBNP further elucidated in Table 1 initiation of norepinephrine to support blood pressure with diuresis. Finally, the IL-6 inhibitor tocilizumab at 4 mg/kg (400mg) was administered as a single infusion. Within 24 hours the patient's oxygenation and hemodynamics improved as evidenced by a P/F ratio of 246, cessation of norepinephrine, and reduction in milrinone. On hospital day 7 an aldose reductase inhibitor (ARI) currently known as AT-001 was initiated at a dose of 1500 mg every 12 hours for a 14 day course. Over the next three days the patient was weaned off NMB, milrinone, and FiO2/PEEP until extubation on hospital day 10 (total of 7 days of mechanical ventilation), and eventually discharged on hospital day 19. The COVID-19 pandemic has rendered tremendous morbidity and mortality claiming 120,000 lives at a rate of at least 4% since the first reported death in China on January 11, 2020. The virus has infected over 2 million people across at least 180 countries in just over three months (1) (2) . The virus invades cells by binding and crossing the cellular membrane via angiotensin-converting enzyme 2. This protein is found in high concentration in pneumocytes and myocytes thus explaining two of the principal organs involved in the disease process. Following initial viremia the infection transitions into a cytokine-release phase that can lead to development of ARDS and acute myocardial inflammation (3). If treatment is delayed or absent the resulting myocarditis may progress to long-term heart failure with irreversible dilatation and tissue fibrosis. Our understanding of this virus and corresponding treatment strategies continues to expand, but remains in an early investigative period. Multiple institutions have released guidelines to assist in management. The majority of guidance focuses on the associated respiratory dysfunction, which is derived from abundant existing data on ARDS management. However, less guidance exists regarding cardiac complications from the virus despite its prevalence and poor prognostication related to the disease. A study from China revealed patients hospitalized for COVID-19 infection developed cardiac injury in roughly 20% of cases leading to greater than 50% mortality (4). A retrospective analysis for cause of death in Chinese patients infected with COVID-19 revealed 40% of patients died at least in part to myocardial injury and circulatory collapse (5). These organ systems do not operate independently and often compound complications. For instance, those with cardiac injury are over 5-fold more likely to require mechanical ventilation (4). We describe a case of COVID-19 infection resulting in critical illness in the form of severe ARDS and suspected myocarditis with ensuing cardiogenic shock. Similar to reported averages, the patient exhibited rapid respiratory failure on hospital day 3 and 10 days after symptom onset. Concomitantly, the patient had a significant rapid rise in troponin without ischemic changes on EKG, and global hypokinesis with relative apical sparing on echocardiogram suggestive of myocarditis. Eventually MRI showed diffuse bi-ventricular and bi-atrial edema with mild LGE making myocarditis the most likely etiology to the acute cardiac injury in this context. Other reasonable but less likely etiologies include stress cardiomyopathy (inverted variant/reverse Takotsubo's given apical sparing), ACS, or demand ischemia. In stress cardiomyopathy over 95% of cases exhibit EKG changes, and MRI shows edema without LGE in the areas of regional wall motion abnormalities (RWMA). Additionally, reverse Takotsubo's cardiomyopathy makes up less than 5% of cases, further decreasing its likelihood (6) . Given the absence of EKG changes, minimal CAC on chest CT, and RWMA outside of coronary distributions ACS was also improbable. Further investigation with endomyocardial biopsy to confirm the histologic diagnosis of myocarditis was deferred given the risk of the procedure, the critical state of the patient, and the goal to minimize viral exposure to healthcare personnel. Angiograms to evaluate coronary disease or swan-ganz catheters to assess hemodynamics were avoided for similar reasons. These limitations will pose ongoing diagnostic and therapeutic uncertainty in COVID-19 patients with cardiac injury. Reliance on clinical acumen and noninvasive techniques will be required to guide management. Treatment of our patient's myocarditis with high dose IV corticosteroids was guided by treatment of other forms of fulminant myocarditis (7) . Additionally, some studies indicate mortality benefit and reduced duration of mechanical intubation in ARDS including observational data from China (8) (9) . When the patient's respiratory and hemodynamic status worsened in the setting of persistently elevated inflammatory markers, an IL-6 inhibitor tocilizumab was infused. Tocilizumab has FDA approval for treating inflammatory conditions like rheumatoid arthritis and giant cell arteritis. It also carries an off-label use for treating cytokine release syndrome, which may help attenuate this phase of COVID-19 infection. A Chinese study reported positive outcomes for its use in treating COVID-19 pneumonia and Phase III clinical trials are currently underway in the US (10) . Subsequently, an ARI currently known as AT-001 was initiated aimed at further mitigating pulmonary and cardiac inflammatory sequelae. In the setting of endotoxins, ARI's have shown reduced inflammatory markers, recovery of cardiac function, and mortality benefit in animal models (11) . Improved airway inflammation has also been observed in animals treated with ARIs (12) . SARS-CoV-2 principally invades pneumocytes and myocytes generating a significant inflammatory cascade that can render critical illness in the form of ARDS and cardiac injury associated with high mortality. The differential diagnosis for cardiac injury in COVID-19 mainly includes myocarditis, ACS, demand ischemia, and stress cardiomyopathy. Our case highlights the use of noninvasive methods for early detection and differentiation of cardiac injury. Early aggressive treatment of suspected myocarditis with IV corticosteroids followed by tocilizumab and AT-001 likely contributed to our patient's full recovery. • Prevalence and prognostic implications of cardiac injury (defined as troponin elevation >99th percentile upper reference limit) in coronavirus disease 2019 (COVID-19). • Considerations for differentiating etiologies of cardiac injury in COVID-19 infection. • Management strategies for myocarditis and severe acute respiratory distress syndrome (ARDS) in COVID-19 infection. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention COVID-19 Map. Johns Hopkins Coronavirus COVID-19: what has been learned and to be learned about the novel coronavirus disease Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology Cardio-Immunology of myocarditis: Focus on immune mechanisms and treatment options. Front Cardiovasc Med Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Effective treatment of severe COVID-19 patients with tocilizumab Endotoxin-Induced Cardiomyopathy and Systemic Inflammation in Mice Is Prevented by Aldose Reductase Inhibition Circulation Inhibition of aldose reductase prevents experimental allergic airway inflammation in mice